Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis

BACKGROUND: High levels of serum interleukin-6 (IL-6) correlate with disease severity in COVID-19. We hypothesized that tocilizumab (a recombinant humanized anti-IL-6 receptor) could improve outcomes in selected patients with severe worsening COVID-19 pneumonia and high inflammatory parameters. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Roumier, Mathilde, Paule, Romain, Vallée, Alexandre, Rohmer, Julien, Ballester, Marie, Brun, Anne-Laure, Cerf, Charles, Chabi, Marie-Laure, Chinet, Thierry, Colombier, Marie-Alice, Farfour, Eric, Fourn, Erwan, Géri, Guillaume, Khau, David, Marroun, Ibrahim, Ponsoye, Matthieu, Roux, Antoine, Salvator, Hélène, Schoindre, Yoland, Si Larbi, Anne-Gaëlle, Tchérakian, Colas, Vasse, Marc, Verrat, Anne, Zuber, Benjamin, Couderc, Louis-Jean, Kahn, Jean-Emmanuel, Groh, Matthieu, Ackermann, Félix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666405/
https://www.ncbi.nlm.nih.gov/pubmed/33188624
http://dx.doi.org/10.1007/s10875-020-00911-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666405/
https://www.ncbi.nlm.nih.gov/pubmed/33188624
http://dx.doi.org/10.1007/s10875-020-00911-6

Ejemplares similares